[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: Thrombolytics & Fibrinolytics

May 2013 | 38 pages | ID: C57940F1ECCEN
La Merie Publishing

US$ 330.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The Competitive Intelligence Report Thrombolytics & Fibrinolytics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel thrombolytics and fibrinolytics for treatment of cardiovascular thrombosis, stroke and eye diseases. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report provides information on the various generation of marketed thrombolytics and includes a compilation of current active projects in research and development of novel thrombolytics and fibrinolytics including those in development in ophthalmology and in less regulated markets. In addition, the report lists company-specific product portfolios and R&D pipelines of thrombolytics and fibrinolytics. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
  • Non-fibrin selective (1st generation) Fibrinolytics
  • Fibrin selective wild-type t-PA-based Fibrinolytics
  • Fibrin selective engineered t-PA-based Fibrinolytics
  • Non-t-PA-based Fibrinolytics
  • Plasmin-based Fibrinolytics
  • Adjunctive therapy to Fibrinolytics
  • Biosimilar Thrombolytics and Fibrinolytics in Non-Regulated Markets
  • Corporate Thrombolytic Product Portfolios and R&D Pipelines


More Publications